Targeted Therapy for Metastatic Colorectal Cancer
prIME Decision Points
prIME Decision Points

Targeted Therapy for Metastatic Colorectal Cancer

Addressing Practical Challenges

Not a member of My prIME? Join now for instant access.

Hear from the experts on the optimal use of targeted therapy for metastatic colorectal cancer (mCRC). Practical challenges like treatment sequence, third-line therapy, and management of high microsatellite instability (MSI-H) will be discussed. A clinical scenario with patient history, laboratory results, and options for next steps in treatment provide commentary and insight for decision making in the care of your patients with mCRC.

Interactive Presentation

Interactive Presentation

Downloadable Slides

Downloadable Slides

CME

CME

0.75 AMA PRA Category 1 Credit™

Release Date

Release Date

Oct 13, 2017

Expiration Date

Oct 13, 2018

  • Axel Grothey, MDMayo Clinic
    Rochester, Minnesota, United States
  • Alberto Sobrero, MDOspedale San Martino
    Genova, Italy

Case 1: Treatment sequencing in mCRC across the disease continuum

Featured Experts: Axel Grothey, MD

Case 2: Optimizing third-line therapy in mCRC

Featured Experts: Axel Grothey, MD

Case 3: Managing MSI-H mCRC

Featured Experts: Axel Grothey, MD

This activity is intended for medical oncologists, gastroenterologists, radiation and surgical oncologists, and other healthcare professionals involved in the management of patients with metastatic colorectal cancer.

After successful completion of this educational activity, participants should be able to:

  • Describe findings from recent clinical trials that can help determine an appropriate treatment sequence based on individual patient and disease characteristics
  • Distinguish the adverse event profiles associated with treatment options for relapsed mCRC, as well as dose adjustment strategies for management of treatment-related complications
  • Select an appropriate dose of therapy for patients with mCRC

This educational activity is supported by a grant from Bayer HealthCare Pharmaceuticals, Inc.

Continuing Education

prIME Oncology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Targeted Therapy for Metastatic Colorectal Cancer - prIME Oncology

prIME Oncology designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Method of Participation

There are no fees for participating in and receiving CME credit for this activity. In order to receive credit, participants must successfully complete the online posttest and activity evaluation. Your participation in this CME activity will be recorded in prIME Oncology’s database. However, upon request, your CME credit certificate will be emailed to you. Technical requirements may be found under the Terms of Use.

A link to the posttest is available on the video player pages.

In order to receive credit, participants must successfully complete the online posttests with 75% or higher.

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity:

Dr Grothey has disclosed that he has received consulting fees from Bayer, Genentech, Boehringer Ingelheim, Boston Biomedicals, Eli Lilly, and Taiho. He also disclosed that he has performed contracted research for Bayer, Boston Biomedicals, and Genentech. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Sobrero has disclosed that he had received consulting fees from Amgen, Bayer, Bristol-Myers Squibb, Celgene, Lilly, Merck, Roche, and Sanofi. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Bojana Pajk, MD (medical director content reviewer/planner) – no relevant financial relationships
  • Beth Cameron, PhD (clinical content reviewer/planner) – no relevant financial relationships
  • Sanneke Koekkoek, RN (clinical content reviewer/planner) – no relevant financial relationships
  • Trudy Stoddert, ELS (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.